Chemical Proteomic Probes for Profiling Cytochrome P450 Activities and Drug Interactions In Vivo

Chemistry and Biology

Volumn 14, Issue 9, 2007, Pages 1043-1051

  Wright, Aaron T ^a   Cravatt, Benjamin F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

CHEMBIO

Indexed keywords

2 ETHYNYLNAPHTHALENE; 2-ETHYNYLNAPHTHALENE; CYTOCHROME P450; ENZYME INHIBITOR; NAPHTHALENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG INTERACTION; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR PROBE; MOUSE; PROTEOMICS; SYNTHESIS;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MICE; MOLECULAR PROBES; NAPHTHALENES; PROTEOMICS;

EID: 34548628220     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2007.08.008     Document Type: Article

References (55)

1. Denisov I.L., Makris T.M., Sligar S.G., and Schlichting I. Structure and chemistry of cytochrome P450. Chem. Rev. 105 (2005) 2253-2277
2. Guengerich F.P., Wu Z.-L., and Bartleson C.J. Function of human cytochrome P450s: characterization of the orphans. Biochem. Biophys. Res. Commun. 338 (2005) 465-469
3. Meunier B., de Visser S.P., and Shaik S. Mechanism of oxidation reactions catalyzed by cytochrome P450 enzymes. Chem. Rev. 104 (2004) 3947-3980
4. Brueggemeier R.W., Hackett J.C., and Diaz-Cruz E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 26 (2005) 331-345
5. Wienkers L.C., and Heath T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4 (2005) 825-833
6. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31 (2003) 815-832
7. Lin J.H., and Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35 (1998) 361-390
8. Guengerich F.P. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8 (2006) E101-E111
9. Rodrigues A.D., and Rushmore T.H. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr. Drug Metab. 3 (2002) 289-309
10. Bachmann K.A. Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug-drug interactions: pitfalls, progress, and promise. Curr. Drug Metab. 7 (2006) 1-14
11. Marathe P.H., and Rodrigues A.D. In vivo animal models for investigating potential CYP3A- and Pgp-mediated drug-drug interactions. Curr. Drug Metab. 7 (2006) 687-704
12. Shou M. Prediction of pharmacokinetics and drug-drug interactions from in vitro metabolism data. Curr. Opin. Drug Discov. Devel. 8 (2005) 66-77
13. Hughes A.L., Powell D.W., Bard M., Eckstein J., Barbuch R., Link A.J., and Espenshade P.J. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab. 5 (2007) 143-149
14. Aguiar M., Masse R., and Gibbs B.F. Regulation of cytochrome P450 by posttranslational modification. Drug Metab. Rev. 37 (2005) 379-404
15. Oesch-Bartlomowicz B., and Oesch F. Phosphorylation of cytochrome P450 isoenzymes in intact hepatocytes and its importance for their function in metabolic processes. Arch. Toxicol. 64 (1990) 257-261
16. Venkatakrishnan K., von Moltke L.L., Court M.H., Harmatz J.S., Crespi C.L., and Greenblatt D.J. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratio of accessory proteins as sources of discrepancies between the approaches. Drug Metab. Dispos. 28 (2000) 1493-1504
17. 2-receptor antagonists: relationship between intrinsic potency and effective plasma concentrations. Clin. Pharmacokinet. 20 (1991) 218-236
18. Knodell R.G., Browne D.G., Gwozdz G.P., Brian W.R., and Guengerich F.P. Differential inhibition of individual human liver cytochromes P-450 by cimetidine. Gastroenterology 101 (1991) 1680-1691
19. Chang T., Levine M., Bandiera S.M., and Bellward G.D. Selective inhibition of rat hepatic microsomal P-450. I. Effect of the in vivo administration of cimetidine. J. Pharmacol. Exp. Ther. 260 (1991) 1441-1449
20. Chang T., Levine M., and Bellward G.D. Selective inhibition of rat hepatic microsomal P-450. II. Effect of the in vitro administration of cimetidine. J. Pharmacol. Exp. Ther. 260 (1991) 1450-1455
21. 18O stable isotope labeling. Mol. Cell. Proteomics 6 (2007) 953-962
22. Kent U.M., Jushchyshyn M.I., and Hollenberg P.F. Mechanism-based inactivators as probes of cytochrome P450 structure and function. Curr. Drug Metab. 2 (2001) 215-243
23. Foroozesh M., Primrose G., Guo Z., Bell L.C., Alworth W.L., and Guengerich F.P. Aryl acetylenes as mechanism-based inhibitors of cytochrome P450-dependent monooxygenase enzymes. Chem. Res. Toxicol. 10 (1997) 91-102
24. Roberts E.S., Hopkins N.E., Foroozesh M., Alworth W.L., Halpert J.R., and Hollenberg P.F. Inactivation of cytochrome P450S 2B1, 2B4, 2B6, and 2B11 by arylalkynes. Drug Metab. Dispos. 25 (1997) 1242-1248
25. Ortiz de Montellano P.R., and Mico B.A. Branchpoint for heme alkylation and metabolite formation in the oxidation of aryl acetylenes by cytochrome P450. J. Biol. Chem. 260 (1985) 3330-3336
26. Hammons G.J., Alworth W.L., Hopkins N.E., Guengrich F.P., and Kadlubar F.D. 2-ethynylnaphthalene as a mechanism-based inactivator of the cytochrome P-450 catalyzed N-oxidation of 2-naphthylamine. Chem. Res. Toxicol. 2 (1989) 367-374
27. Yun C.-H., Hammons G.J., Jones G., Martin M.V., Hopkins N.E., Alworth W.L., and Guengerich F.P. Modification of cytochrome P450 1A2 enzymes by the mechanism-based inactivator 2-ethynylnaphthalene and the photoaffinity label 4-azidobiphenyl. Biochemistry 31 (1992) 10556-10563
28. Beebe L.E., Roberts E.S., Fornwald L.W., Hollenberg P.F., and Alworth W.L. Mechanism-based inhibition of P4502b-10 by selected arylalkynes. Biochem. Pharmacol. 52 (1996) 1507-1513
29. Evans M.J., and Cravatt B.F. Mechanism-based profiling of enzyme families. Chem. Rev. 106 (2006) 3279-3301
30. Jessani N., and Cravatt B.F. The development and application of methods for activity-based protein profiling. Curr. Opin. Chem. Biol. 8 (2004) 54-59
31. Sadaghiani A.M., Verhelst S.H., and Bogyo M. Tagging and detection strategies for activity-based proteomics. Curr. Opin. Chem. Biol. 11 (2007) 20-28
32. Speers A.E., Adam G.C., and Cravatt B.F. Activity-based protein profiling in vivo using a copper(I)-catalyzed azide-alkyne [3+2] cycloaddition. J. Am. Chem. Soc. 125 (2003) 4686-4687
33. Speers A.E., and Cravatt B.F. Profiling enzyme activities in vivo using click chemistry methods. Chem. Biol. 11 (2004) 535-546
34. Kolb H.C., Finn M.G., and Sharpless K.B. Click chemistry: diverse chemical function from a few good reactions. Angew. Chem. Int. Ed. 40 (2001) 2004-2021
35. Washburn M.P., Wolters D., and Yates J.R. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat. Biotechnol. 19 (2001) 242-247
36. Jessani N., Niessen S., Wei B.Q., Nicolau M., Humphrey M., Ji Y., Han W., Noh D.Y., Yates III J.R., Jeffrey S.S., and Cravatt B.F. A streamlined platform for high-content functional proteomics of primary human specimens. Nat. Methods 2 (2005) 691-697
37. Zhang Q.-Y., Dunbar D., and Kaminsky L.S. Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab. Dispos. 31 (2003) 1346-1351
38. Helsby N.A., Chipman J.K., Gescher A., and Kerr D. Inhibition of mouse and human CYP 1A- and 2E1-dependent substrate metabolism by the isoflavonoids genistein and equol. Food Chem. Toxicol. 36 (1998) 375-382
39. Lee B.-Y., Park S.R., Jeon H.B., and Kim K.S. A new solvent system for the efficient synthesis of 1,2,3-triazoles. Tetrahedron Lett. 47 (2006) 5105-5109
40. Agundez J.A.G. Cytochrome P450 gene polymorphism and cancer. Curr. Drug Metab. 5 (2004) 211-224
41. Patterson L.H., and Murray G.I. Tumour cytochrome P450 and drug activation. Curr. Pharm. Des. 8 (2002) 1335-1347
42. McFadyen M.C.E., Melvin W.T., and Murray G.I. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol. Cancer Ther. 3 (2004) 363-371
43. Poirier A., Funk C., Lavé T., and Noé J. New strategies to address drug-drug interactions involving OATPs. Curr. Opin. Drug Discov. Devel. 10 (2007) 74-83
44. Nishikawa A., Mori Y., Lee I.S., Tanaka T., and Hirose M. Cigarette smoking, metabolic activation and carcinogenesis. Curr. Drug Metab. 5 (2004) 363-373
45. Guengerich F.P. Human cytochrome P450 enzymes. In: Ortiz de Montellano P.R. (Ed). Cytochrome P450 (2005), Kluwer Academic/Plenum, New York 377-530
46. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34 (2002) 83-448
47. Guengerich F.P. Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. Chem. Biol. Interact. 106 (1997) 161-182
48. Nelson D.R., Zeldin D.C., Hoffman S.M.G., Maltais L.J., Wain H.M., and Nebert D.W. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14 (2004) 1-18
49. Gonzalez F.J., and Kimura S. Study of P450 function using gene knockout and transgenic mice. Arch. Biochem. Biophys. 409 (2003) 153-158
50. Gonzalez F.J., and Yu A.-M. Cytochrome P450 and xenobiotic receptor humanized mice. Annu. Rev. Pharmacol. Toxicol. 46 (2006) 41-64
51. Katoh M., Matsui T., Nakajima M., Tateno C., Kataoka M., Soeno Y., Horie T., Iwasaki K., Yoshizato K., and Yokoi T. Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab. Dispos. 32 (2004) 1402-1410
52. Katoh M., Watanabe M., Tabata T., Sato Y., Nakajima M., Nishimura M., Naito S., Tateno C., Iwasaki K., Yoshizato K., and Yokoi T. In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica 35 (2005) 863-875
53. Evans M.J., Saghatelian A., Sorensen E.J., and Cravatt B.F. Target discovery in small-molecule cell-based screens in situ proteome reactivity profiling. Nat. Biotechnol. 23 (2005) 1303-1307
54. Guengerich F.P. Analysis and characterization of enzymes and nucleic acids. In: Hayes A.W. (Ed). Principles and Methods of Toxicology (1994), Raven Press, New York 1259-1313
55. Clark B.J., and Waterman M. Heterologous expression of mammalian P450 in COS cells. Methods Enzymol. 206 (1991) 100-108